Plasma cystatin C is a predictor of renal dysfunction, acute‐on‐chronic liver failure, and mortality in patients with acutely decompensated liver cirrhosis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Hepatology

• Publication date

  2017-05-25

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/hep.29290PMID 28545169
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Neutrophil gelatinase-associated lipocalin is a biomarker of acute-on-chronic liver failure and prognosis in cirrhosis.

  2016influential reference
• Kidney biomarkers in cirrhosis.

  2016influential reference
• Neutrophil Gelatinase-Associated Lipocalin: A New Marker of Renal Function in C-Related End Stage Liver Disease

  2015cited by this paper
• Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites

  2015cited by this paper
• Benefit of cystatin C in evaluation of renal function and prediction of survival in patients with cirrhosis

  2015cited by this paper
• Comparative Assessment of Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Cystatin C as Early Biomarkers for Early Detection of Renal Failure in Patients with Hypertension

  2015cited by this paper
• The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure.

  2015cited by this paper
• Biomarkers of renal function, which and when?

  2015cited by this paper
• Evaluation of Serum Cystatin C as a Marker of Early Renal Impairment in Patients with Liver Cirrhosis

  2015cited by this paper
• Analysis of a Urinary Biomarker Panel for Clinical Outcomes Assessment in Cirrhosis

  2015cited by this paper
• Neutrophil Gelatinase Associated Lipocalin (NGAL) – a biomarker of renal dysfunction in patients with liver cirrhosis: Do we have enough proof?

  2015cited by this paper
• Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure.

  2014cited by this paper
• Creatinine‐ versus cystatine C‐based equations in assessing the renal function of candidates for liver transplantation with cirrhosis

  2014cited by this paper
• Evaluation of renal function in patients with cirrhosis: where are we now?

  2014cited by this paper
• Performance of chronic kidney disease epidemiology collaboration creatinine‐cystatin C equation for estimating kidney function in cirrhosis

  2014cited by this paper
• Current Concepts in the Diagnosis and Classification of Renal Dysfunction in Cirrhosis

  2013cited by this paper
• Original ResearchFull Report: Clinical—LiverNew Consensus Definition of Acute Kidney Injury Accurately Predicts 30-Day Mortality in Patients With Cirrhosis and Infection

  2013cited by this paper
• Predicting the development of acute kidney injury in liver cirrhosis – an analysis of glomerular filtration rate, proteinuria and kidney injury biomarkers

  2013cited by this paper
• Acute kidney injury in patients with cirrhosis: perils and promise.

  2013cited by this paper
• Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis.

  2013influential reference
• Association of AKI With mortality and complications in hospitalized patients with cirrhosis

  2013cited by this paper
• Cystatin C is a biomarker for predicting acute kidney injury in patients with acute-on-chronic liver failure.

  2013cited by this paper
• Estimating glomerular filtration rate from serum creatinine and cystatin C.

  2012cited by this paper
• Renal failure and cirrhosis: a systematic review of mortality and prognosis.

  2012cited by this paper
• Cystatin C and acute changes in glomerular filtration rate.

  2012cited by this paper
• Acute kidney injury in decompensated cirrhosis

  2012cited by this paper
• Cystatin C: a predictor of hepatorenal syndrome in patients with liver cirrhosis

  2011cited by this paper
• Cystatin C is a good predictor of hepatorenal syndrome and survival in patients with cirrhosis who have normal serum creatinine levels.

  2011cited by this paper
• Difficulties in assessing renal function in patients with cirrhosis: potential impact on patient treatment

  2011cited by this paper
• Increased urinary neutrophil gelatinase associated lipocalin in urinary tract infections and leukocyturia

  2011cited by this paper
• Prognostic importance of the cause of renal failure in patients with cirrhosis.

  2011cited by this paper
• Serum Neutrophil Gelatinase-Associated Lipocalin – A Sensitive Novel Marker of Renal Impairment in Liver Cirrhosis?

  2011cited by this paper
• Renal failure in cirrhosis.

  2009cited by this paper
• Early Diagnosis of Acute Kidney Injury: The Promise of Novel Biomarkers

  2009cited by this paper
• Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis.

  2009cited by this paper
• Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD.

  2008influential reference
• Review article: renal function assessment in cirrhosis – difficulties and alternative measurements

  2007cited by this paper
• How to estimate GFR-serum creatinine, serum cystatin C or equations?

  2007cited by this paper
• Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis

  2007cited by this paper
• Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis.

  2002cited by this paper
• Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver

  2002cited by this paper
• Relationships among serum cystatin C, serum creatinine, lean tissue mass and glomerular filtration rate in healthy adults.

  1999cited by this paper

• Taurochenodeoxycholic acid as a sensitive stratification marker for HBV-associated hepatic cirrhosis status has a hepatoprotective effect

  2025cites this paper
• Nephroprotective potential of robinin to counteract aldicarb induced renal dysfunction via modulating TLR4/MyD88, HMGBI/RAGE, NF-κB pathway: A biochemical and pharmacodynamic approach.

  2025cites this paper
• Emerging trends in the cystatin C sensing technologies: towards better chronic kidney disease management

  2025cites this paper
• Understanding and Treating Hepatorenal Syndrome: Insights from Recent Research

  2025cites this paper
• Update on Hepatorenal Syndrome: From Pathophysiology to Treatment.

  2025cites this paper
• AKI in ACLF: navigating the complex therapeutic puzzle

  2025cites this paper
• Noninvasive assessment of renal dysfunction in patients with end-stage liver disease: new solutions for old problems?

  2025cites this paper
• Zonula occludens 1 as a novel biomarker in decompensated alcoholic cirrhosis with hepatorenal syndrome

  2025cites this paper
• Understanding acute kidney injury in cirrhosis: Current perspective

  2025cites this paper
• Cystatin C as a predictor of renal recovery and in hospital mortality in patients with acute kidney injury and liver cirrhosis

  2025cites this paper
• Acute Kidney Injury in Patients with Liver Cirrhosis: From Past to Present Definition and Diagnosis

  2025cites this paper
• Renal Complications in Portal Hypertension.

  2024cites this paper
• Evaluation of Acute Kidney Injury (AKI) Biomarkers FABP1, NGAL, Cystatin C and IL-18 in an Indian Cohort of Hospitalized Acute-on-chronic Liver Failure (ACLF) Patients.

  2024cites this paper
• Study of the role of D-dimer in the prediction of hepatorenal syndrome in cirrhotic Egyptian patients

  2024cites this paper
• Prospective evaluation of cystatin C in the assessment of kidney dysfunction and survival in liver transplant candidates

  2024cites this paper
• Cystatin C and the difference between cystatin C and serum creatinine: Improved metrics to predict waitlist mortality among patients with decompensated cirrhosis

  2024cites this paper
• Biomarkers in acute kidney injury and cirrhosis

  2024cites this paper
• Seeing and Sensing the Hepatorenal Syndrome (HRS): The Growing Role of Ultrasound-Based Techniques as Non-Invasive Tools for the Diagnosis of HRS

  2024cites this paper
• APASL clinical practice guidelines on the management of acute kidney injury in acute-on-chronic liver failure

  2024cites this paper
• Acute kidney injury in patients with cirrhosis: Acute Disease Quality Initiative (ADQI) and International Club of Ascites (ICA) joint multidisciplinary consensus meeting

  2024cites this paper
• Acute Kidney Injury in Acute on Chronic Liver Failure Versus Decompensated Cirrhosis—What Is the Difference?

  2024cites this paper
• From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury.

  2024cites this paper
• HEPATORENAL SYNDROME IN CIRRHOSIS.

  2024cites this paper
• Association of Cystatin C Level with All-cause Mortality in Patients with Liver Cirrhosis: A Meta-analysis.

  2024cites this paper
• Advances in the management of complications from cirrhosis

  2023cites this paper
• Non‐resolution of acute kidney injury in the first week portends the development of chronic kidney disease in critically ill patients with cirrhosis

  2023cites this paper
• Kidney disease in patients with chronic liver disease: Does sex matter?

  2023cites this paper
• Acute kidney injury in patients with acute-on-chronic liver failure: clinical significance and management

  2023cites this paper
• Causal relationship between polycystic ovary syndrome and chronic kidney disease: A Mendelian randomization study

  2023cites this paper
• Plasma human neutrophil peptides as biomarkers of disease severity and mortality in patients with decompensated cirrhosis

  2023cites this paper
• Cystatin C as A Prognostic Biomarker to Monitor Renal Function in Liver Cirrhosis: A Narrative Review

  2023cites this paper
• Editorial: Unmasking the silent threat—acute kidney injury in alcohol‐associated hepatitis

  2023cites this paper
• Novel prognostic biomarkers in decompensated cirrhosis: a systematic review and meta-analysis

  2023cites this paper
• Overestimated renal function in patients with liver cirrhosis predicts poor prognosis

  2022cites this paper
• Sarcopenia HIBA score predicts sarcopenia and mortality in patients on the liver transplant waiting list

  2022cites this paper
• Assessment of glomerular filtration rate in patients with cirrhosis: Available tools and perspectives

  2022cites this paper
• Assessment of kidney function in cirrhosis: Are we moving closer to accurate estimation of glomerular filtration rate?

  2022cites this paper
• Feasibility of the MELD score as a screening tool for pharmacists to identify patients with impaired hepatic function at hospital admission

  2022cites this paper
• Management of hepatorenal syndrome in liver cirrhosis: a recent update

  2022cites this paper
• Predictive value of lipocalin 2 and cystatin C for acute kidney injury in patients with cirrhosis.

  2022cites this paper
• Novel biomarkers of acute kidney injury in chronic liver disease: Where do we stand after a decade of research?

  2022cites this paper
• Novel Biomarkers of AKI in Cirrhosis

  2022cites this paper
• The diagnostic and prognostic utility of serum cystatin C and angiopoietin 2 in patients with liver cirrhosis complicated by acute kidney injury

  2022cites this paper
• Management of Decompensated Cirrhosis in the Surgical ICU: an American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document

  2022cites this paper
• Research Status of Prognostic Indicators and Prediction Models of Acute-on-Chronic Liver Failure

  2022cites this paper
• Role of Serum Cystatin C as a Diagnostic Tool for Renal Function in Cirrhotic Patients

  2022cites this paper
• Role of Novel Kidney Biomarkers in Patients With Cirrhosis and After Liver Transplantation

  2021influential citation
• Cystatin C and interleukin‐6 for prognosticating patients with acute decompensation of cirrhosis

  2021cites this paper
• Monitoring Renal Function and Therapy of Hepatorenal Syndrome Patients with Cirrhosis.

  2021cites this paper
• Development and Validation of a Nomogram For Predicting Drug-Induced Acute Kidney Injury in Hospitalized Patients

  2021cites this paper
• Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation.

  2021cites this paper
• Development and Validation of a Nomogram for Predicting Drug-Induced Acute Kidney Injury in Hospitalized Patients: A Case-Control Study Based on Propensity-Score Matching

  2021cites this paper
• End‐stage liver disease: Management of hepatorenal syndrome

  2021cites this paper
• Current knowledge about biomarkers of acute kidney injury in liver cirrhosis

  2021influential citation
• [Clinical Value of Cystatin C-Based Estimated Glomerular Filtration Rate in Assessing Short-Term Mortality in Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure Treated with Artificial Liver Support System].

  2021cites this paper
• Update on blood‐based biomarkers for chronic liver diseases prognosis: Literature review and institutional experience

  2021cites this paper
• Plasma Cystatin C Level is a Prognostic Marker of Morbidity and Mortality in Hospitalized Decompensated Cirrhotic Patients.

  2021cites this paper
• Baseline serum cystatin C as a marker of acute kidney injury in patients with acute-on-chronic liver failure

  2021cites this paper
• Acute kidney injury: prediction, prognostication and optimisation for liver transplant

  2020cites this paper
• The value of ascitic neutrophil gelatinase‐associated lipocalin in decompensated liver cirrhosis with spontaneous bacterial peritonitis

  2020cites this paper
• Review Article Review of Serum Biomarkers and Models Derived from Them in HBV-Related Liver Diseases

  2020cites this paper
• CYSTATIN C AS A SCREENING BIOMARKER OF GESTATIONAL DIABETES MELLITUS

  2020cites this paper
• Renal disease in the allograft recipient.

  2020cites this paper
• Review of Serum Biomarkers and Models Derived from Them in HBV-Related Liver Diseases

  2020cites this paper
• Acute Life-Threatening Complications of Portal Hypertension: a Review of Pathophysiology, Incidence, Management, and Cost

  2020cites this paper
• Prognosis predictability of serum and urine renal markers in patients with decompensated cirrhosis: A multicentre prospective study

  2020cites this paper
• Clinical Application of Kidney Biomarkers in Cirrhosis.

  2020influential citation
• Cystatin C as a biomarker of chronic kidney disease: latest developments

  2020cites this paper
• Latest Treatment of Acute Kidney Injury in Cirrhosis

  2020cites this paper
• Effects of shenkang injection on renal angiogenesis in mice with unilateral ureteral obstruction

  2020cites this paper
• Fluid Biomarkers for Predicting the Prognosis of Liver Cirrhosis

  2020cites this paper
• Effect of terlipressin on renal function in cirrhotic patients with acute upper gastrointestinal bleeding

  2020cites this paper
• Paradigmenwechsel im Verständnis der akuten Nierenschädigung bei chronischer Leberinsuffizienz: Von der Pathophysiologie zur Definition von Krankheitsentitäten

  2020cites this paper
• Beyond Metabolism: Role of the Immune System in Hepatic Toxicity

  2020cites this paper
• Cystatin C and Sarcopenia Predict Acute on Chronic Liver Failure Development and Mortality in Patients on the Liver Transplant Waiting List

  2020cites this paper
• Cystatin C: The answer or a call for better kidney biomarkers in cirrhosis?

  2020cites this paper
• Admission Plasma Uromodulin and the Risk of Acute Kidney Injury in Hospitalized Patients with Cirrhosis: a Pilot Study.

  2019cites this paper
• Serum cystatin C is increased in acute spinal cord injury: a multicentre retrospective study

  2019cites this paper
• Development and Validation of a Model to Predict Acute Kidney Injury in Hospitalized Patients With Cirrhosis

  2019cites this paper
• Sex specificity of kidney markers to assess prognosis in cirrhotic patients with TIPS

  2019cites this paper
• A Critical Review of MELD as a Reliable Tool for Transplant Prioritization

  2019cites this paper
• Aktualisierte S2k-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) „Komplikationen der Leberzirrhose“

  2019cites this paper
• Aktualisierte S2k-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) „Komplikationen der Leberzirrhose“

  2019cites this paper
• Impact of NGAL (Neutrophil Gelatinase Associated lipocalin) on Outcome of Hepato-renal Syndrome

  2019cites this paper
• Serum Cystatin C Predicts Mortality in HBV-Related Decompensated Cirrhosis

  2019cites this paper
• Assessment of renal function in cirrhosis: Sarcopenia, gender and ethnicity matter.

  2019cites this paper
• Clinical utility of urinary neutrophil gelatinase-associated lipocalin and serum cystatin C in a cohort of liver cirrhosis patients with renal dysfunction: a challenge in the diagnosis of hepatorenal syndrome

  2019cites this paper
• The Development and Outcome of Acute‐on‐Chronic Liver Failure After Surgical Interventions

  2019cites this paper
• Role of biomarkers as predictors of acute kidney injury and mortality in decompensated cirrhosis

  2019cites this paper
• Hepatorenal syndrome

  2018cites this paper
• Assessment and prediction of acute kidney injury in patients with decompensated cirrhosis with serum cystatin C and urine N‐acetyl‐β‐D‐glucosaminidase

  2018cites this paper
• The Combination of Serum Cystatin C, Urinary Kidney Injury Molecule-1 and MELD plus Score Predicts Early Acute Kidney Injury after Liver Transplantation

  2018cites this paper
• Renal Function in Cirrhosis: A Critical Review of Available Tools

  2018cites this paper
• Renale und pulmonale Komplikationen der Leberzirrhose

  2018cites this paper
• Beyond serum creatinine: which tools to evaluate renal function in cirrhotic patients?

  2018cites this paper
• Cystatin C Is a Gender-Neutral Glomerular Filtration Rate Biomarker in Patients with Cirrhosis

  2018cites this paper
• Hepatocytes and neutrophils cooperatively suppress bacterial infection by differentially regulating lipocalin‐2 and neutrophil extracellular traps

  2018cites this paper
• Serum NGAL Is Superior to Cystatin C in Predicting the Prognosis of Acute-on-Chronic Liver Failure.

  2018cites this paper
• Prognostic utility of novel biomarkers in acute‐on‐chronic liver failure (ACLF) associated with hepatitis B: A multicenter prospective study

  2018cites this paper